Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03808077 · ClinicalTrials.gov registry record · Phase 2

The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer

A Phase 2 study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 2
Development phase
139
Enrollment target
1
Study location

NCT03808077: Active Phase 2 study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT03808077 is a Phase 2 study of Prostate Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 139 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03808077, a Phase 2 study of Prostate Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
139 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if there is a difference in intra-abdominal pressure which surgeons use during surgery and post-surgery pain in men who undergo robotic prostate surgery with deep neuromuscular blockade (NMB), compared with moderate NMB.

Primary Outcome

Measured by continuous Intra-abdominal Pressure monitor in mmHg.

Conditions Studied

Interventions

  • DRUG Rocuronium 0.3mg/kg/hr
  • DRUG Rocuronium 1.5mg/kg/hr

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 139 participants
Start Date 2019-01-14
Est. Completion 2027-01
Phase Phase 2
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT03808077 still lists

NCT03808077 is an interventional study that assigns participants to a tested intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (77% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Rocuronium 0.3mg/kg/hr is the first listed.

NCT03808077 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT03808077 about?

NCT03808077 is a clinical study titled "The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer". The purpose of this study is to determine if there is a difference in intra-abdominal pressure which surgeons use during surgery and post-surgery pain in men who undergo robotic prostate surgery with deep neuromuscular blockade (NMB), compared with moderate NMB.

What is the current status of trial NCT03808077?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 139 participants. The study started on 2019-01-14. Estimated completion is 2027-01.

What conditions does trial NCT03808077 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT03808077?

The interventions under investigation include: Rocuronium 0.3mg/kg/hr (DRUG), Rocuronium 1.5mg/kg/hr (DRUG).

Who is sponsoring clinical trial NCT03808077?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03808077 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03808077's enrollment target sits among peer trials

139 281st of 735 higher than 455 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05645380 · 139 participants · Phase 2

    Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

  • NCT06239272 · 139 participants · Phase 1

    NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

  • NCT06252220 · 139 participants · Phase 1

    First in Human Study in Subjects With Obesity, But Otherwise Healthy

  • NCT06537128 · 139 participants · NA

    Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03808077, the US trial registry maintained by the National Library of Medicine. NCT03808077 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.